European Antibody Congress 2008

Schedule of Presentations:

Monday, December 1, 2008
08:00:00 Registration and coffee
09:00:00 Chairman’s opening remarks Alain Beck
09:05:00 Keynote presentation: isotype selection in monoclonal antibody engineering: choosing the right format for success Andrew Goodearl
09:30:00 Natural IgG4 half antibodies, in vivo bispecific antibody rearrangement and implications for IgG4 anti-inflammatory activity Rob C Aalberse
09:55:00 Antibody epitope mapping: structural basis for better functional activity understanding Alain Beck
10:20:00 Speed networking
11:20:00 Morning coffee
11:40:00 Case studies on structure-function analysis Paul Parren
12:05:00 Enhancing IP protection via epitope mapping Kathleen M. Williams
12:30:00 The Bifunctional Hybrid Protein (BHP), a new enabling technology for non-linear epitope mapping Fabrizio Giannotta
12:55:00 Lunch
14:00:00 V region engineering to reduce immunogenicity and enhance functional and biophysical properties Juan Carlos Almagro
14:25:00 Stability-engineered IgG-like tetravalent antibody inducing receptor-mediated death in leukaemia cells Scott M Glaser
14:50:00 Engineering antibodies in a competitive environment Tristan Vaughan
15:15:00 Engineering differentiating pharmacology in monoclonal antibodies using protein- and glycoengineering Laurent Audoly
15:40:00 Afternoon tea
16:10:00 Design of therapeutic antibodies with maximum effector functions, based on the natural IgG isotype and its oligosaccharide heterogeneity Mitsuo Satoh
16:35:00 Glycosylation strategies for enhancing antibody effector functions Qun Zhou
17:00:00 GA101, a novel glycoengineered type II CD20 antibody with outstanding anti-tumor efficacy and superior B cell depletion Christian Klein
17:25:00 The pro- and anti-inflammatory activities of IgG Falk Nimmerjahn
17:50:00 Panel session: translation of antibody structure-function knowledge in clinical drug candidates Alain Beck, Andrew Goodearl, Luc Alain Savoy, Tristan Vaughan
18:20:00 Close of day one followed by networking drinks
Tuesday, December 2, 2008
08:00:00 Registration and coffee
09:00:00 Chairman’s opening remarks Clive Wood
09:05:00 An evidence-based perspective on emerging trends and developments in the monoclonal antibodies sector Janice Reichert
09:30:00 Antibody lead discovery and development: a case study in successful pipeline development Prof Jan van de Winkel
09:55:00 A European regulator's perspective on monoclonal antibody development and regulation Kowid Ho
10:20:00 Morning coffee
10:50:00 Considerations for formulation, and enhancing the 'drug-like' qualities of monoclonal antibodies Tudor Arvinte
11:15:00 Delivery of monoclonal antibodies: State of the art delivery and associated challenges Steffan Bassarab
11:40:00 Investigating and circumventing resistance to therapeutic monoclonal antibodies Charles Dumontet
12:05:00 Immunogenicity assessment of antibody therapeutics – Bioanalytical strategy and risk-based approach Patrick Liu
12:30:00 Lunch on your own
13:30:00 Patenting and Intellectual Property Jonathan Evans Klein
13:55:00 Biosimilar antibodies – an approaching reality or a distant dream? Keith Watson
14:20:00 Optimizing the production of monoclonal antibodies in mammalian cells Hitto Kaufmann
14:45:00 Real-time control of antibody development and the productions process to support a Quality by Design approach Andreas Schneider
15:10:00 Afternoon tea
15:40:00 Discovery and development of cancer antibodies using functional screens Daniel Pereira
15:40:00 Afternoon tea
16:05:00 Discovery of anticancer monoclonal antibodies targeting JAM-A by functional approaches Nathalie Corvaïa
16:30:00 Quantification of recombinant monoclonal antibodies in biological fluids for faster biotherapeutic development Francis Bitsch
16:55:00 Close of day two followed by networking drinks
Wednesday, December 3, 2008
09:00:00 Chairman’s opening remarks Robert J Lutz
09:05:00 Development of advanced antibody-based therapeutics in oncology Robert J Lutz
09:35:00 Keynote presentation: Trastuzumab DM1 (T-DM1): an advanced antibody-drug conjugate based on Herceptin Mark Sliwkowski
10:05:00 Auristatin Based Antibody-Drug Conjugates: Preclinical and Clinical Update Hans Peter Gerber
10:35:00 Human antibody-MGBA conjugates for cancer therapy David King
11:05:00 Morning coffee
11:35:00 Development of a dual-specific antibody technology: DVD-Ig Chengbin Wu
12:05:00 An update on bispecific T-Cell Engager (BITE ®) technology Christian Itin
12:35:00 Adnectins™: realizing the promise of a novel class of targeted biologics Eric Furfine
13:05:00 Lunch
14:05:00 Engineering repeat proteins for tumour-targeting Andreas Plückthun
14:35:00 Protease inhibitors from phage display Clive Wood
15:05:00 Pulmonary delivery delivered domain antibodies as drugs Ben Woolven
15:35:00 Afternoon tea
16:00:00 Antibody variable and constant domains as scaffolds: domain antibodies and nanoantibodies Dimiter S Dimitriov
16:30:00 Small antibody-mimicking structures for therapeutic applications Christian Heinis
17:00:00 Panel discussion: assessing the market impact of domain/fragment approaches on classical antibody development Robert J Lutz, Mark Sliwkowski, Clive Wood, Eric Furfine
17:30:00 Close of Congress
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.